- Home
- APCX vs IMRN Comparison
APCX vs IMRN Comparison
Compare APCX & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APCX
- IMRN
- Stock Information
- Founded
- APCX 2006
- IMRN 1994
- Country
- APCX United States
- IMRN Australia
- Employees
- APCX N/A
- IMRN N/A
- Industry
- APCX Finance: Consumer Services
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- APCX Finance
- IMRN Health Care
- Exchange
- APCX Nasdaq
- IMRN Nasdaq
- Market Cap
- APCX 11.7M
- IMRN 10.1M
- IPO Year
- APCX N/A
- IMRN N/A
- Fundamental
- Price
- APCX $0.44
- IMRN $1.75
- Analyst Decision
- APCX
- IMRN Strong Buy
- Analyst Count
- APCX 0
- IMRN 1
- Target Price
- APCX N/A
- IMRN $5.00
- AVG Volume (30 Days)
- APCX 77.1K
- IMRN 13.7K
- Earning Date
- APCX 05-13-2025
- IMRN 04-15-2025
- Dividend Yield
- APCX N/A
- IMRN N/A
- EPS Growth
- APCX N/A
- IMRN N/A
- EPS
- APCX N/A
- IMRN N/A
- Revenue
- APCX $276,000.00
- IMRN $4,048,286.00
- Revenue This Year
- APCX $1,315.48
- IMRN N/A
- Revenue Next Year
- APCX N/A
- IMRN N/A
- P/E Ratio
- APCX N/A
- IMRN N/A
- Revenue Growth
- APCX N/A
- IMRN 82.90
- 52 Week Low
- APCX $0.31
- IMRN $1.70
- 52 Week High
- APCX $1.49
- IMRN $3.09
- Technical
- Relative Strength Index (RSI)
- APCX 57.44
- IMRN 41.07
- Support Level
- APCX $0.37
- IMRN $1.73
- Resistance Level
- APCX $0.43
- IMRN $2.09
- Average True Range (ATR)
- APCX 0.03
- IMRN 0.14
- MACD
- APCX 0.01
- IMRN 0.00
- Stochastic Oscillator
- APCX 93.38
- IMRN 10.26
About APCX AppTech Payments Corp.
AppTech Payments Corp is a FinTech company utilizing various payment processing and digital banking technologies to complement core merchant services capabilities. The company's patented and proprietary software will provide progressive and adaptable products that are available through a suite of synergistic offerings directly to merchants, banking institutions, and business enterprises. It is developing a secure digital payments and banking platform that powers commerce experiences for clients and customers. Based upon industry standards for payment and banking protocols, the company will offer standalone products and fully integrated solutions that deliver unparalleled payments, banking, and financial services experiences.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.